Eleva Unveils Groundbreaking Research in Fight Against AMD

Eleva is making waves in the field of ophthalmology with the release of exciting new data on its flagship treatment, CPV-104, a cutting-edge recombinant variant of human complement factor H. Featured in the esteemed Journal of Neuroinflammation, this research is a significant leap toward combating age-related macular degeneration (AMD), a leading cause of vision loss.

CPV-104’s Promising Results in Animal Models

In rigorous animal testing, CPV-104 showcased its potential by significantly reducing key indicators of AMD. Eleva's findings reveal that this innovative therapy effectively curbs inflammation in the eye by targeting microglia and Müller cells, two culprits in retinal degeneration. Not only does it show promise in protecting the retina from light-induced damage, but it also paves the way for future human applications.

Experts Weigh In on the Implications of CPV-104

Andreas Schaaf, PhD, Eleva's Chief Scientific Officer, expressed enthusiasm about the data, stating, "This demonstrates a monumental step forward for CPV-104. Our program continues to yield positive results, not just for rare complement-related disorders but also for widespread conditions like dry AMD. These findings bolster our plans to expand into related areas, moving beyond our initial focus on C3 Glomerulopathy (C3G)."

Collaborative Efforts Amplify Success

Collaborating with the University of Cologne, Eleva has also documented significant improvements in retinal health through intravitreal injections of CPV-104, shedding light on its neuroprotective and immunomodulatory properties. These studies indicate that CPV-104 could play a crucial role in delaying or halting the progression of dry AMD in human patients.

A Bright Future Ahead for Eleva

Eleva, an innovative biopharmaceutical company, is committed to developing previously unreachable biologics. With an extensive pipeline that includes groundbreaking therapies for complement disorders and enzyme replacement treatments, CPV-104 is slated to enter clinical trials for C3 Glomerulopathy in early 2025, with dry AMD as a secondary focus. The company’s aGal (RPV-001) program, aimed at treating Fabry disease, recently completed a successful Phase 1b clinical trial. Leveraging transformative moss-based technology, Eleva is poised to manufacture previously undruggable proteins with immense therapeutic potential.

Stay Tuned for the Full Study!

The full publication, titled "Moss-derived human complement factor H modulates retinal immune response and attenuates retinal degeneration,” is now available for review in the Journal of Neuroinflammation, offering a deeper look into how CPV-104 could revolutionize the treatment landscape for AMD and beyond.